1. Giangrande P. Haemophilia B: christmas disease.Expert Opin Pharmacother. 2005;6(9):1517-24. [DOI:10.1517/14656566.6.9.1517] [PMID]

2. Camerino G, Grzeschik KH, Jaye M, De La Salle H, Tolstoshev P, Lecocq JP,et al. Regional localization on the human X chromosome and polymorphism of the coagulation factor IX gene (Hemophilia B locus). Proc Natl Acad Sci USA. 1984;81(2):498-502. [DOI:10.1073/pnas.81.2.498] [PMID] []

3. Ghasemi F, Zomorodipour A, Karkhane AA, Khorramizadeh MR. In silico designing of hyper-glycosylated analogs for the human coagulation factor IX. J Mol Graph Model.2016;68:39-47. [DOI:10.1016/j.jmgm.2016.05.011] [PMID]

4. Chia J, Louber J, Glauser I, Taylor S, Bass GT, Dower SK, et al.Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway. J Biol Chem. 2018;293(17):6363-73. [DOI:10.1074/jbc.M117.817064] [PMID] []

5. Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C.. Treatment of hemophilia B: focus on recombinant factor IX. Biologics. 2013;7:33-38. [DOI:10.2147/BTT.S31582] [PMID] []

6. Kundu RK, Sangiorgi F, Wu LY, Kurachi K, Anderson WF, Maxson R, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood. 1998;92(1):168-74. [DOI:10.1182/blood.V92.1.168.413k06_168_174] [PMID]

7. Franchini Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7(1):1-8. [DOI:10.1186/1750-1172-7-24] [PMID] []

8. Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C,et al.Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405-11. [DOI:10.1182/blood-2012-05-429688] [PMID] []

9. Sankar AD, Weyand AC, Pipe SW. The evolution of recombinant factor replacement for hemophilia. Transfusion and Apheresis Science. Transfus Apher Sci. 2019;58(5):596-600. [DOI:10.1016/j.transci.2019.08.010] [PMID]

10. Jayandharan GR, Srivastava A. Hemophilia: genetics, diagnosis and treatment.J Genet Syndr Gene Ther. 2011;1:1-12. [DOI:10.4172/2157-7412.S1-005]

11. White II GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78(1):261-5. [DOI:10.1055/s-0038-1657536]

12. Zacchi LF, Roche-Recinos D, Pegg CL, Phung TK, Napoli M, Aitken C,et al.Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product. Communications Biology. 2021;4(1):1-19. [DOI:10.1038/s42003-021-01903-x] [PMID] []

13. Windyga J, Solano Trujillo MH, Hafeman AE. BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B.Ther Adv Hematol. 2014;5(5):168-80. [DOI:10.1177/2040620714550573] [PMID] []

14. Pegg CL, Zacchi LF, Recinos DR, Howard CB, Schulz BL. Identification of novel glycosylation events on human serum-derived Factor IX. Glycoconjugate Journal. 2020;37(4):471-83. [DOI:10.1007/s10719-020-09922-2] [PMID]

15. Zhong D, Smith KJ, Birktoft JJ, Bajaj SP. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natil Acad Sci. 1994;91(9):3574-8. [DOI:10.1073/pnas.91.9.3574] [PMID] []

16. Ghasemi F, Khorramizadeh MR, Karkhane AA, Zomorodipour A. Studying the Expression Efficiencies of Human Clotting Factor IX Analogs, Rationally Designed for Hyper-glycosylation. Iran J Pharm Res. 2021;20(2):523-535.

17. Nielsen FS, Schmidt AS, Kristensen AK, Nielsen AD, Kristensen BK, Palm L. Characterisation of recombinant factor IX before and after GlycoPEGylation. Int J Pharm. 2020;588:119654. [DOI:10.1016/j.ijpharm.2020.119654] [PMID]

18. Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR. Proteolytic processing of human coagulation factor IX by plasmin. Blood. 2000;95(3):943-51. [DOI:10.1182/blood.V95.3.943.003k34_943_951] [PMID]

19. Tuddenham EG, Cooper DN. The molecular genetics of haemostasis and its inherited disorders Oxford University Press, USA; 1994.

20. Kim JY, Kim YG, Lee GM, CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol. 2012; 93(3):917-30. [DOI:10.1007/s00253-011-3758-5] [PMID]

21. Croset A, Delafosse L, Gaudry J-P, Arod C, Glez L, Losberger C,et al.Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J Biotechnol. 2012;161(3):336-48. [DOI:10.1016/j.jbiotec.2012.06.038] [PMID]

22. Gurtu V, Yan G, ZhangG. IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines. Biochem Biophys Res Commun. 1996;229(1):295-8. [DOI:10.1006/bbrc.1996.1795] [PMID]

23. Khorshidi S, Zomorodipour A, Behmanesh M, Vatandoost J, Bos MH. Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences inmammalian cell line. Biotechnol lett. 2012;37(10):1773-1781. [DOI:10.1007/s10529-015-1868-3] [PMID]